OPCs are plant compounds sold as grape seed or pine bark supplements for circulation and healthy aging. Small trials suggest small, uncertain drops in blood pressure and, in type 2 diabetes, long-term blood sugar, plus modest menopausal and leg vein relief; several independent trials found none. Trial side effects were mild; added lowering alongside medication and poor product quality matter more. Research is partly maker-funded; no human aging data exist. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood pressure | Below 120/80 mmHg | Expected to change; safety check on antihypertensives |
| HbA1c | Below 5.7% | Expected to change in type 2 diabetes |
| Fasting glucose | 70–99 mg/dL | Safety check on diabetes drugs |
| LDL cholesterol | Below 100 mg/dL | Expected to change modestly |
| INR (on warfarin only) | No established target for OPC use; track change from stable INR | Safety check on anticoagulant dosing |
Cadence: Baseline before the first dose; home blood pressure weekly for the first 4–6 weeks, then monthly; INR one to two weeks after starting on warfarin; fasting glucose, HbA1c and lipids at 12 weeks, then every 6–12 months